Last reviewed · How we verify

NCT04581642: MoNOLog

Nociception-Level (NOL) for the Assessment of Pain in Patient Unable to Self-Report

Completed Last updated 14 December 2021
What this trial tests

trial testing PMD200 in Pain in 33 participants. Completed in 30 November 2021.

Timeline
1 November 2020
Primary endpoint
30 August 2021
30 November 2021

Quick facts

Lead sponsorMedasense Biometrics Ltd
StatusCompleted
Study typeOBSERVATIONAL
Enrollment33
Start date1 November 2020
Primary completion30 August 2021
Estimated completion30 November 2021
Sites1 location across Israel

Drugs / interventions tested

Conditions studied

Sponsor

Medasense Biometrics Ltd — full company profile →

Who can join

18 and older, any sex, with Pain or Opioid Use. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this study we aimed to investigate the performance and effectiveness of NOL and/or NOLedge as a tool for pain assessment in geriatric and critical ill non communicating patients. Our hypothesis was that NOL and the NOLedge may have good correlation with the health-care professional assessment PAINAD, BPS values, even with the use of the drugs affecting autonomic nervous system.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Pain

Currently open trials in the same condition.

Other Medasense Biometrics Ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04581642.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing